Mesothelioma or ovarian carcinoma? A case reportFALKSON, C. I.SAMJ. South African medical journal. 1985, Vol 68, Num 9, pp 676-677, issn 0256-9574Article

Fludarabine : A phase II trial in patients with previously treated low-grade lymphomaFALKSON, C. I.American journal of clinical oncology. 1996, Vol 19, Num 3, pp 268-270, issn 0277-3732Article

Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanomaFALKSON, C. I.Medical oncology (Northwood). 1995, Vol 12, Num 1, pp 35-40, issn 1357-0560Article

New formulation intravenous melphalan in the treatment of patients with metastatic renal cancerFALKSON, C. I.Investigational new drugs. 1993, Vol 11, Num 1, issn 0167-6997, p. 93Article

Current approaches in the management of patients with hepatocellular carcinomaFALKSON, G; FALKSON, C. I.Oncology research. 1992, Vol 4, Num 3, pp 87-89, issn 0965-0407Article

A phase II evaluation of clofazimine plus doxorubicin in advanced, unresectable primary hepatocellular carcinomaFALKSON, C. I; FALKSON, G.Oncology. 1999, Vol 57, Num 3, pp 232-235, issn 0030-2414Article

Extended survival in 80 patients with operable, locoregionally recurrent breast cancer treated with chemotherapyEEK, R. W; FALKSON, C. I.American journal of clinical oncology. 1998, Vol 21, Num 5, pp 501-504, issn 0277-3732Article

A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancerFALKSON, C. I; FALKSON, H. C.Annals of oncology. 1996, Vol 7, Num 5, pp 465-470, issn 0923-7534, 5 p.Article

Ifosfamide and Mesna in the treatment of malignant disease Mesna as urothelial protectorFALKSON, C. I; FALKSON, H. C; FALKSON, G et al.Investigational new drugs. 1989, Vol 7, Num 2-3, pp 261-267, issn 0167-6997Article

High-dose medroxyprogesterone acetate plus mitomycin-C or vindesine in the treatment of advanced breast cancerFALKSON, C. I; FALKSON, H. C; FALKSON, G et al.American journal of clinical oncology. 1988, Vol 11, Num 4, pp 431-434, issn 0277-3732Article

Prognostic factors in metastatic malignant melanoma : An analysis of 236 patients treated on clinical research studies at the Department of Medical Oncology, University of Pretoria, South Africa from 1972-1992FALKSON, C. I; FALKSON, H. C.Oncology. 1998, Vol 55, Num 1, pp 59-64, issn 0030-2414Article

Phase II trial of fotemustine in patients with metastatic malignant melanomaFALKSON, C. I; FALKSON, G; FALKSON, H. C et al.Investigational new drugs. 1994, Vol 12, Num 3, pp 251-254, issn 0167-6997Article

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanomaFALKSON, C. I; FALKSON, G; FALKSON, H. C et al.Journal of clinical oncology. 1991, Vol 9, Num 8, pp 1403-1408, issn 0732-183XArticle

Carcinoma of unknown primary site : Leave it unknownMCMICHAEL, G. B; FALKSON, C. I.SAMJ. South African medical journal. 1999, Vol 89, Num 8, pp 844-845, issn 0256-9574Conference Paper

Current treatment options for malignant melanomaCOHEN, G. L; FALKSON, C. I.Drugs (Basel). 1998, Vol 55, Num 6, pp 791-799, issn 0012-6667Article

Granulocyte-macrophage-colony-stimulating factor support in patients with acute non-lymphatic leukemiaNEL, J. S; FALKSON, C. I.Oncology. 1996, Vol 53, Num 6, pp 482-487, issn 0030-2414Article

Antiemetic efficacy of tropisteron in patients failing previous antiemetic therapyFALKSON, C. I; FALKSON, H. C.Oncology. 1995, Vol 52, Num 5, pp 427-431, issn 0030-2414Article

Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary originFALKSON, C. I; COHEN, G. L.Oncology. 1998, Vol 55, Num 2, pp 116-121, issn 0030-2414Article

Cyclophosphamide, doxorubicin and fluorouracil (CAF) plus depo-buserelin in the treatment of premenopausal women with metastatic breast cancerFALKSON, C. I; FALKSON, H. C; FALKSON, G et al.Annals of oncology. 1992, Vol 3, Num 10, pp 849-853, issn 0923-7534Article

Cisplatin versus cisplatin plus D-Trp-6-LHRH in the treatment of ovarian cancer : A pilot trial to investigate the effect of the addition of a GnRH analogue to cisplatinFALKSON, C. I; FALKSON, H. C; FALKSON, G et al.Oncology. 1996, Vol 53, Num 4, pp 313-317, issn 0030-2414Article

Effect of chemotherapy with or without Buserelin on serum hormone levels in premenopausal women with breast cancerFALKSON, C. I; FALKSON, H. C; FALKSON, G et al.European journal of cancer : (1990). 1991, Vol 27, Num 10, pp 1208-1211Article

High versus low dose granisetron, a selective 5HT₃ antagonist, for the prevention of chemotherapy-induced nausea and vomitingFALKSON, H. C; FALKSON, C. I; FALKSON, G et al.Investigational new drugs. 1990, Vol 8, Num 4, pp 407-409, issn 0167-6997, 3 p.Article

A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemiaHOCEPIED, A. M. L. J; FALKSON, C. I; FALKSON, G et al.SAMJ. South African medical journal. 1996, Vol 86, Num 5, pp 549-550, issn 0256-9574Article

FIVB plus GM-CSF in metastatic colorectal cancerFALKSON, C. I; FALKSON, G; FALKSON, H. C et al.Investigational new drugs. 1994, Vol 12, Num 1, pp 49-52, issn 0167-6997Article

Treatment of squamous cell esophageal cancer with topotecan: An Eastern Cooperative Oncology Group Study (E2293)ASBURY, R. F; LIPSITZ, S; GRAHAM, D et al.American journal of clinical oncology. 2000, Vol 23, Num 1, pp 45-46, issn 0277-3732Article